$1.0M
3 filings since 2025 · latest Equity filed
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment through pioneering biologically-based therapies. The company is firmly committed to addressing the pressing challenge of drug resistance in cancer treatment by developing innovative medications that work by reactivating cell death mechanisms.
What sets it apart
Cyclacel stands out through its focused research on cell cycle biology and its commitment to addressing unmet medical needs in oncology and hematology, thereby improving patient outcomes.
Cyclacel Pharmaceuticals develops a range of therapeutic candidates aimed at overcoming cancer drug resistance utilizing targeted approaches in cell cycle biology, transcriptional regulation, and mitosis biology. These innovative treatments are designed to tackle cancers that have proven challenging for conventional therapies.
